eCite Digital Repository

Risk of venous thromboembolism, use of enoxaparin and clinical outcomes in obese patients undergoing laparoscopic adjustable gastric band surgery: A retrospective study

Citation

Hussain, Z and Peterson, GM and Mirkazemi, C and Curtain, C and Zaidi, STR, Risk of venous thromboembolism, use of enoxaparin and clinical outcomes in obese patients undergoing laparoscopic adjustable gastric band surgery: A retrospective study, Medicine pp. 1-6. ISSN 0304-5412 (2020) [Refereed Article]


Preview
PDF
280Kb
  

Copyright Statement

Copyright 2020 the Author(s). Licensed under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) https://creativecommons.org/licenses/by-nc/4.0/

Official URL: https://journals.lww.com/md-journal/Fulltext/2020/...

DOI: doi:10.1097/MD.0000000000020174

Abstract

There is a lack of clear guidance for the prophylactic use of anticoagulants for patients undergoing laparoscopic adjustable gastric banding (LAGB) surgery.

This study aimed to evaluate the risk of venous thromboembolism (VTE), prophylactic use of enoxaparin and clinical outcomes in patients undergoing primary and revisional LAGB procedures.

A retrospective study evaluated the prophylactic use of enoxaparin in adult patients who underwent primary and revisional (band and port) LAGB procedures. The incidence of VTE and major bleeding was investigated during a 90-day follow-up period. Descriptive and inferential statistics were used for data analysis.

We included 112 and 100 patients who had undergone primary and revisional (24 band procedures and 76 port procedures) LAGB surgery, respectively. The majority of patients (97%) had a mild risk of VTE development using a post-discharge VTE risk calculator tool published from the Cleveland Clinic. All primary procedure patients received prophylactic enoxaparin, compared to 79% and 20% of revisional patients who underwent band and port procedures, respectively (P < .001). The overall VTE incidence was 0.9%, with no significant difference between patients who did or did not receive chemoprophylaxis (0.7% and 1.5%, respectively; P = .58). No major bleeding events were observed.

may not be required in all patients undergoing low-risk LAGB surgery unless there are additional risk factors, such as the presence of super-super-morbid obesity or concomitant hormone replacement therapy. More studies are needed on the prophylactic use and dosing of enoxaparin in patients undergoing LAGB procedures to provide high-level evidence.

Item Details

Item Type:Refereed Article
Keywords:dose, enoxaparin, laparoscopic adjustable gastric banding, obese, prophylaxis, surgery
Research Division:Medical and Health Sciences
Research Group:Pharmacology and Pharmaceutical Sciences
Research Field:Clinical Pharmacology and Therapeutics
Objective Division:Health
Objective Group:Clinical Health (Organs, Diseases and Abnormal Conditions)
Objective Field:Surgical Methods and Procedures
UTAS Author:Hussain, Z (Mr Zahid Hussain)
UTAS Author:Peterson, GM (Professor Gregory Peterson)
UTAS Author:Mirkazemi, C (Mrs Corinne Mirkazemi)
UTAS Author:Curtain, C (Mr Colin Curtain)
UTAS Author:Zaidi, STR (Dr Tabish Razi Zaidi)
ID Code:138899
Year Published:2020
Deposited By:Pharmacy
Deposited On:2020-05-09
Last Modified:2020-06-25
Downloads:0

Repository Staff Only: item control page